Evidence map›Paper›PMID 42519117›Full record

ArticleInternational journal of pharmaceutics: X2026

Extended release of DELOS nanovesicles from thermoreversible in situ-forming subcutaneous depots.

Carla Castellar-Álvarez, Lídia Ballell-Hosa, Yolanda Ronda-Lopez, Aniol Gimó-Santamaria, Arnau Güell-Bara, Cristián Huck-Iriart, Jan Skov Pedersen, Alba Córdoba, Santi Sala, Nora Ventosa and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Carla Castellar-ÁlvarezNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Lídia Ballell-HosaNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Yolanda Ronda-LopezNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Aniol Gimó-SantamariaNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Arnau Güell-BaraNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Cristián Huck-IriartALBA Synchrotron Light Source, 08290 Cerdanyola del Vallès, Spain.
Jan Skov PedersenDepartment of Chemistry and Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus, C, Denmark.
Alba CórdobaNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Santi SalaNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Nora VentosaInstitut de Ciència dels Materials de Barcelona, ICMAB-CSIC, 08193 Cerdanyola del Vallès, Spain.
Elisabet González-MiraInstitut de Ciència dels Materials de Barcelona, ICMAB-CSIC, 08193 Cerdanyola del Vallès, Spain.
Lidia Ferrer-TasiesNanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing transition from traditional orally bioavailable small molecules to novel drug modalities demands advanced drug delivery strategies. This work presents the development of a hybrid,

Indexed as

Extended releaseIn-situ depotNanovesiclesPoloxamer 407Subcutaneous drug deliveryThermoreversible hydrogel

Identifiers

PMID42519117
PMCPMC13382603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.